Sangamo Therapeutics, Inc.

Symbol: 0R1D.L




Market price today

  • -0.3877

    P/E Ratio

  • 0.0181

    PEG Ratio

  • 114.62M

    MRK Cap

  • 0.00%

    DIV Yield

Sangamo Therapeutics, Inc. (0R1D-L) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Medical - Pharmaceuticals
CEO:Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Full-time employees:405
City:Brisbane California
Address:501 Canal Blvd

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

General Outlook

In simple terms, Sangamo Therapeutics, Inc. has 196.648 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.885% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.649%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -1.463%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -1.560% return, is a testament to Sangamo Therapeutics, Inc.'s adeptness in optimizing resource deployment. Sangamo Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.310%. Furthermore, the proficiency of Sangamo Therapeutics, Inc. in capital utilization is underscored by a remarkable -0.972% return on capital employed.

Stock Prices

Sangamo Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $1.16, while its low point bottomed out at $1.07. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Sangamo Therapeutics, Inc.'s stock market.

Liquidity Ratios

Analyzing 0R1D.L liquidity ratios reveals its financial health of the firm. The current ratio of 197.62% gauges short-term asset coverage for liabilities. The quick ratio (172.48%) assesses immediate liquidity, while the cash ratio (94.71%) indicates cash reserves.

Current Ratio197.62%
Quick Ratio172.48%
Cash Ratio94.71%

Profitability Ratios

0R1D.L profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -149.18% underscores its earnings before tax deductions. The effective tax rate stands at 1.93%, revealing its tax efficiency. The net income per EBT, 98.07%, and the EBT per EBIT, 230.03%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -64.85%, we grasp its operational profitability.

Pretax Profit Margin-149.18%
Effective Tax Rate1.93%
Net Income per EBT98.07%
EBT per EBIT230.03%
EBIT per Revenue-64.85%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.98, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 13290.50% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

Days of Sales Outstanding172
Operating Cycle2.75
Days of Payables Outstanding275
Cash Conversion Cycle-272
Receivables Turnover132.90
Payables Turnover1.33
Fixed Asset Turnover3.33
Asset Turnover1.07

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.27, and free cash flow per share, -1.38, depict cash generation on a per-share basis. The cash per share value, 0.46, showcases liquidity position. Lastly, the operating cash flow sales ratio, -1.28, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-1.27
Free Cash Flow per Share-1.38
Cash per Share0.46
Operating Cash Flow Sales Ratio-1.28
Free Cash Flow to Operating Cash Flow Ratio1.09
Cash Flow Coverage Ratio-49.00
Short Term Coverage Ratio-49.00
Capital Expenditure Coverage Ratio-10.63
Dividend Paid and Capex Coverage Ratio-10.63

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 2.78%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.06, we discern the balance between debt and equity financing.

Debt Ratio2.78%
Debt Equity Ratio0.06
Total Debt to Capitalization5.25%
Cash Flow to Debt Ratio-49.00
Company Equity Multiplier1.99

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 1.01, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.48, reflects the portion of profit attributed to each share. The book value per share, 0.48, represents the net asset value distributed per share, while the tangible book value per share, 0.48, excludes intangible assets.

Revenue Per Share1.01
Net Income Per Share-1.48
Book Value Per Share0.48
Tangible Book Value Per Share0.48
Shareholders Equity Per Share0.48
Interest Debt Per Share0.03
Capex Per Share-0.12

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 58.34%, indicates top-line expansion, while the gross profit growth, 55.30%, reveals profitability trends. EBIT growth, 43.22%, and operating income growth, 43.22%, offer insights into operational profitability progression. The net income growth, -34.09%, showcases bottom-line expansion, and the EPS growth, -18.40%, measures the growth in earnings per share.

Revenue Growth58.34%
Gross Profit Growth55.30%
EBIT Growth43.22%
Operating Income Growth43.22%
Net Income Growth-34.09%
EPS Growth-18.40%
EPS Diluted Growth-18.40%
Weighted Average Shares Growth13.02%
Weighted Average Shares Diluted Growth13.02%
Operating Cash Flow Growth-0.54%
Free Cash Flow Growth-0.90%
10-Year Revenue Growth per Share134.32%
5-Year Revenue Growth per Share15.96%
3-Year Revenue Growth per Share14.92%
10-Year Operating CF Growth per Share-270.32%
5-Year Operating CF Growth per Share-441.85%
3-Year Operating CF Growth per Share-202.01%
10-Year Net Income Growth per Share-210.74%
5-Year Net Income Growth per Share-109.68%
3-Year Net Income Growth per Share-64.23%
10-Year Shareholders Equity Growth per Share-78.15%
5-Year Shareholders Equity Growth per Share-87.43%
3-Year Shareholders Equity Growth per Share-87.18%
Receivables Growth-70.35%
Inventory Growth-100.00%
Asset Growth-70.61%
Book Value per Share Growth-75.14%
Debt Growth-11.61%
R&D Expense Growth-7.78%
SGA Expenses Growth-25.11%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 92,367,968.8, captures the company's total value, considering both debt and equity. Income quality, 0.87, assesses the reliability of reported earnings.

Enterprise Value92,367,968.8
Income Quality0.87
Research and Development to Revenue130.77%
Capex to Operating Cash Flow9.41%
Capex to Revenue-12.00%
Capex to Depreciation-95.33%
Stock-Based Compensation to Revenue-20.23%
Graham Number3.98
Return on Tangible Assets-155.96%
Working Capital46,597,000
Tangible Asset Value82,887,000
Net Current Asset Value11,895,000
Average Receivables2,899,000
Average Payables18,838,500
Average Inventory0.5
Days Sales Outstanding3
Days Payables Outstanding251

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.21, and the price to book ratio, 1.21, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.65, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -0.47, and price to operating cash flows, -0.44, gauge market valuation against cash flow metrics.

Price Book Value Ratio1.21
Price to Book Ratio1.21
Price to Sales Ratio0.65
Price Cash Flow Ratio-0.44
Price Earnings to Growth Ratio0.02
Enterprise Value Multiple-1.29
Price Fair Value1.21
Price to Operating Cash Flow Ratio-0.44
Price to Free Cash Flows Ratio-0.47
Price to Tangible Book Ratio1.20
Enterprise Value to Sales0.52
Enterprise Value Over EBITDA-1.00
EV to Operating Cash Flow-0.41
Earnings Yield-259.21%
Free Cash Flow Yield-247.31%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Sangamo Therapeutics, Inc. (0R1D.L) on the LSE in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.388 in 2024.

What is the ticker symbol of Sangamo Therapeutics, Inc. stock?

The ticker symbol of Sangamo Therapeutics, Inc. stock is 0R1D.L.

What is company IPO date?

IPO date of Sangamo Therapeutics, Inc. is 2014-11-07.

What is company current share price?

Current share price is 0.563 USD.

What is stock market cap today?

The market cap of stock today is 114624350.000.

What is PEG ratio in 2024?

The current 0.018 is 0.018 in 2024.

What is the number of employees in 2024?

In 2024 the company has 405.